There were 108 press releases posted in the last 24 hours and 185,913 in the last 365 days.

National Research Corporation Announces Second Quarter and Year-To-Date 2020 Results

Net New Sales and Total Contract Value Register Impressive Growth

/EIN News/ -- LINCOLN, Neb., Aug. 04, 2020 (GLOBE NEWSWIRE) -- National Research Corporation (NASDAQ:NRC) today announced results for the second quarter of 2020.

Revenue for the quarter ended June 30, 2020, was $31.2 million, compared to $31.4 million for the quarter ended June 30, 2019. Operating income was $9.3 million for the second quarter 2020 compared to $10.1 million for the same quarter 2019. In response to special circumstances among clients hard hit by COVID-19, we elected to provide uncompensated services which reduced revenue without a corresponding offset in expenses, thus impacting operating income. All such impacted clients have resumed compensated services as planned to date and many extended contract terms in recognition of the support provided by NRC Health resulting, we believe, in a stronger partnership. We salute all essential caregivers and are glad we could offer this support.

Net income for the quarter ended June 30, 2020, was $7.7 million, compared to $7.4 million for the quarter ended June 30, 2019. Diluted earnings per share increased to $0.30 for the quarter ended June 30, 2020, from diluted earnings per share of $0.29 for the quarter ended June 30, 2019. Results for the second quarter 2020 included an income tax provision of $842,000 compared with $2.1 million for the same quarter 2019.

Demand for our product portfolio remains strong. Net New Sales were up 6% in the second quarter and 19% year-to-date 2020 compared to 2019, despite a pivot to virtual sales efforts. Based on recent wins, we believe our offerings are highly differentiated in our clients’ eyes against competitive offerings from firms outside of the healthcare industry and legacy vendors within. Case in point, we added healthcare brands Partners HealthCare and Orlando Health this quarter, each seven-figure takeaways from Press Ganey. We believe every added client deepens our moat and brings additive value to all current partners through the network effect.

Total Recurring Contract Value increased 11% in the second quarter 2020, a subset of which is our digital Voice of the Customer offering. VOC now comprises $107 million of Contract Value, up 30% year-over-year. We believe the efficiencies inherent in this digital platform lead to long-term margin improvements, a hallmark of our financial performance, notwithstanding the current quarter impact of COVID-19. Our Voice of the Customer offerings, being uniquely personalized to healthcare, contribute to higher client retention rates as well, compounding the enhancing visibility of recurring revenue streams.

It goes without saying that COVID-19 is far from behind us and we continue to recognize and support the work of our healthcare partners and caregivers worldwide. NRC Health retains its conservative stance regarding liquidity for the security of our associates and optionality as a business. Accordingly, our Board of Directors has determined not to pay a dividend for the current quarter.

A listen-only simulcast of National Research Corporation’s 2020 second quarter conference call will be available online at https://edge.media-server.com/mmc/p/ayrm72gm on August 5, 2020, beginning at 11:00 a.m. Eastern time. The online replay will follow approximately one hour later and continue for 30 days.

For more than 39 years, National Research Corporation has been a leading provider of analytics and insights that facilitate measurement and improvement of human understanding.

This press release contains certain statements that may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such statements are subject to the safe harbor created by those sections and the Private Securities Litigation Reform Act of 1995, as amended. Such statements may be identified by their use of terms or phrases such as “believes,” derivations thereof, and similar terms and phrases. Forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, which could cause future events and actual results to differ materially from those set forth in, contemplated by, or underlying the forward-looking statements, including those risks and uncertainties as set forth in the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, 2019, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, and various disclosures in our press releases, stockholder reports, and other filings with the Securities and Exchange Commission. In this press release, the statements relating to the future status of our partnership with clients and the future impact of adding additional clients are forward-looking statements. We disclaim any obligation to update or revise any forward-looking statements to reflect actual results or changes in the factors affecting the forward-looking information.

Contact: Kevin R. Karas
  Chief Financial Officer
  402-475-2525


NATIONAL RESEARCH CORPORATION AND SUBSIDIARY
Unaudited Condensed Consolidated Statements of Income
(In thousands, except per share data)

  Three months ended
   June 30,    
  Six months ended
   June 30,    
    2020       2019       2020       2019  
         
Revenue $   31,166     $   31,414     $   65,026     $   62,894  
         
Operating expenses:        
Direct expenses   11,634       11,506         24,180         23,160  
Selling, general and administrative   8,852       8,319       17,600       16,026  
Depreciation and amortization     1,405         1,440         2,777         2,855  
  Total operating expenses     21,891         21,265         44,557         42,041  
         
  Operating income   9,275       10,149       20,469       20,853  
         
Other income (expense):        
  Interest income   2       8       13       14  
  Interest expense   (450 )     (533 )     (914 )     (1,103 )
  Other, net     (270 )       (139 )       360         (419 )
         
  Total other expense     (718 )       (664 )       (541 )       (1,508 )
         
  Income before income taxes   8,557       9,485       19,928       19,345  
         
Provision for income taxes     842         2,092         458         3,756  
         
  Net income $   7,715     $   7,393     $   19,470     $   15,589  
         
Earnings Per Share of Common Stock:        
         
Basic Earnings Per Share $     0.31     $     0.30     $   0.78     $   0.63  
Diluted Earnings Per Share $   0.30     $   0.29     $   0.76     $   0.61  
         
Weighted average shares and share equivalents outstanding
  Basic
    25,148         24,789         25,060         24,777  
  Diluted     25,680         25,586         25,702         25,549  

 

NATIONAL RESEARCH CORPORATION AND SUBSIDIARY
Unaudited Condensed Consolidated Balance Sheets
(Dollars in thousands, except share amounts and par value)

  June 30,
2020
    December 31,
2019
 
             
Assets              
Current assets:              
Cash and cash equivalents $ 11,957     $ 13,517  
Accounts receivable, net   19,882       11,639  
Income taxes receivable   272       69  
Other current assets   4,586       3,932  
Total current assets   36,697       29,157  
               
Net property and equipment   12,355       13,530  
Goodwill   57,829       57,935  
Other, net   9,900       10,063  
Total assets $ 116,781     $ 110,685  
               
Liabilities and Shareholders’ Equity              
Current liabilities:              
Notes payable $ 3,966     $ 4,378  
Accounts payable and accrued expenses   3,882       4,687  
Accrued compensation   6,830       6,086  
Income taxes payable   308       366  
Dividends payable   --       5,239  
Deferred revenue   16,275       16,354  
Other current liabilities   1,007       1,045  
Total current liabilities   32,268       38,155  
               
Notes payable, net of current portion   28,627       29,795  
Other non-current liabilities   10,312       9,843  
Total liabilities   71,207       77,793  
               
Shareholders’ equity:              
Preferred stock, $0.01 par value, authorized 2,000,000 shares, none issued   --       --  
Common stock, $0.001 par value; authorized 60,000,000 shares, issued 30,553,546 in 2020 and 30,151,574 in 2019, outstanding 25,235,123 in 2020 and 24,947,500 in 2019   31       30  
Additional paid-in capital   167,808       162,154  
Retained earnings (accumulated deficit)   (79,165     (93,357
Accumulated other comprehensive loss, foreign currency translation adjustment   (2,872 )     (2,209 )
Treasury stock   (40,228 )     (33,726 )
Total shareholders’ equity   45,574       32,892  
Total liabilities and shareholders’ equity $ 116,781     $ 110,685